Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 2/20 | 0.32 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.32 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.32 |
| ▸ | CDK1 | P06493 | 1/20 | 0.32 |
| ▸ | CDK4 | P11802 | 1/20 | 0.32 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.32 |
| ▸ | CCND1 | P24385 | 1/20 | 0.32 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.32 |
| ▸ | CCND2 | P30279 | 1/20 | 0.32 |
| ▸ | CCND3 | P30281 | 1/20 | 0.32 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5339140 | 0.82 | L3MBTL1 (0.34) | CDK2 | |
| SCHEMBL5237928 | 0.75 | MEN1 (0.44) | CDK2CCNB2CCNE2CDK1CDK4 | |
| SCHEMBL5346225 | 0.73 | L3MBTL1 (0.46) | CDK2CCNB2CCNE2CDK1CDK4 | |
| SCHEMBL7142705 | 0.73 | L3MBTL1 (0.35) | CDK2CCNB2CCNE2CDK1CDK4 | |
| Potassium Ion SCHEMBL25246615 | 0.72 | MEN1 (0.34) | CDK2CCNB2CCNE2CDK1CDK4 | |
| SCHEMBL7142710 | 0.69 | FAAH (0.37) | CDK2CCNB2CCNE2CDK1CDK4 | |
| SCHEMBL1983579 | 0.69 | KDM4E (0.42) | CDK2CCNB2CCNE2CDK1CDK4 | |
| SCHEMBL9963871 | 0.69 | CDK2 (0.34) | CDK2CCNB2CCNE2CDK1CDK4 | |
| SCHEMBL7080408 | 0.68 | CDK2 (0.33) | CDK2CCNB2CCNE2CDK1CDK4 | |
| SCHEMBL1980103 | 0.67 | MAPK1 (0.49) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6521759-B2 | Anticancer, antiarthritic, and antiinflammatory agents | BRISTOL-MYERS SQUIBB COMPANY | 2003-02-18 | — | — | US | disclosed |
| US-20020137778-A1 | Aminothiazole inhibitors of cyclin dependent kinases | KIM KYOUNG S (US) | 2002-09-26 | — | — | US | disclosed |
| EP-1240153-A1 | AMINOTHIAZOLE INHIBITORS OF CYCLIN DEPENDENT KINASES | Bristol-Myers Squibb Company (US) | 2002-09-18 | — | — | EP | disclosed |
| US-6262096-B1 | IN COMBINATION WITH A MODULATOR OF P53 TRANSACTIVATION FORMULATED AS A FIXED DOSE. | BRISTOL-MYERS SQUIBB COMPANY | 2001-07-17 | — | — | US | disclosed |
| WO-2001044217-A1 | AMINOTHIAZOLE INHIBITORS OF CYCLIN DEPENDENT KINASES | BRISTOL-MYERS SQUIBB CO. (US) | 2001-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020137778-A1 | Aminothiazole inhibitors of cyclin dependent kinases | CCNI, CDK1, CCNK | CDK2 6/4885CCNB2 37/4885CCNE2 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.